Fecal transplant recipient dies from drug-resistant E coli

  • DeFilipp Z & al.
  • N Engl J Med
  • 30 Oct 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Case report highlights potential for drug-resistant Escherichia coli-containing fecal microbiota transplant (FMT) oral capsules to transfer potentially fatal infections to recipients.
  • Editorial: FMT alternatives needed.

Why this matters

  • Ensure that capsulized FMT is screened before transfer.
  • Weigh FMT benefits with associated risks.

Key points

  • Patient 1: 69-year-old man with hepatitis C-associated liver cirrhosis; open-label study of FMT for refractory hepatic encephalopathy.
  • Regimen: rifaximin prophylaxis before/during/3-week post-FMT treatment (15 FMT capsules × 5 q 3 weeks).
    • Day 17 post-FMT: antibiotics initiated for presumptive pneumonia; 4 days later, diagnostic paracentesis showed extended-spectrum beta-lactamase (ESBL)-producing E coli.
    • Subsequent carbapenem plus 14 days inpatient meropenem, followed by outpatient ertapenem led to clinical stabilization, ESBL clearance.
  • Patient 2: 73-year-old man with therapy-related myelodysplastic syndrome, phase 2 trial to preemptively administer FMT oral capsules pre-/post-allogeneic hematopoietic cell transplantation.
    • Regimen: 15 FMT capsules, day 4, day 3 prehematopoietic cell transplantation plus cefpodoxime prophylaxis day 1 pretransplantation.
    • 8 days post-last FMT dose, developed fever, chills, altered mental status leading to hypoxia, labored breathing, ICU admission. Gram-negative rods on blood culture led to meropenem initiation, condition worsened, patient died 2 days later from sepsis. Final culture: ESBL-producing E coli.
  • Follow-up genome analysis: FMT capsules from same donor.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit